Larotrectinib: First Global Approval-Reference-Cited by-同舟云学术

Larotrectinib: First Global Approval

Published:2019-01-11 Issue:2 Volume:79 Page:201-206
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Scott Lesley J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/article/10.1007/s40265-018-1044-x/fulltext.html

Reference16 articles.

1. Berger S, Martens UM, Bochum S. Larotrectinib (LOXO-101). Recent Results Cancer Res. 2018;211:141–51.

2. Vaishnavi A, Le A, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5(1):25–34.

3. Kummar S, Lassen UN. TRK inhibition: a new tumor-agnostic treatment strategy. Target Oncol. 2018;13(5):545–56.

4. Loxo Oncology. Vitrakvi® (Larotrectinib): US prescribing information. 2018. https://www.fda.gov/ . Accessed 04 Dec 2018.

5. FDA. FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor [media release]. 2018. https://www.fda.gov/ . Accessed 2018.

Cited by 175 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rewriting the textbook for pharma: how to adapt and thrive in a digital, personalized and collaborative world;Drug Discovery Today;2024-09

2. Regioselective Annulation of 3(5)‐Aminopyrazole with Aryl Ketones or Aryl Alkynes Using N,N‐Dimethylethanolamine as a Single/Triple Carbon Synthon;Advanced Synthesis & Catalysis;2024-08-05

3. Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers;Cancer Letters;2024-08

4. Application of Imine Reductase in Bioactive Chiral Amine Synthesis;Organic Process Research & Development;2024-07-11

5. A prognostic model for anoikis-related genes in pancreatic cancer;Scientific Reports;2024-07-02